Ergocalciferol
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00153 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 27 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | familial isolated hypoparathyroidism due to impaired PTH secretion | KG + DL |
| 2 | acromesomelic dysplasia, Campailla Martinelli type | KG + DL |
| 3 | renal tubular acidosis | KG + DL |
| 4 | craniofacial conodysplasia | KG + DL |
| 5 | Dahlberg-Borer-Newcomer syndrome | KG + DL |
| 6 | hypophosphatemia (disease) | KG + DL |
| 7 | renal osteodystrophy | KG + DL |
| 8 | hypophosphatemic rickets | KG + DL |
| 9 | calcium-alkali syndrome | KG + DL |
| 10 | vitamin D-dependent rickets | KG + DL |
| 11 | impaired renal function disease | KG + DL |
| 12 | primary bone dysplasia with defective bone mineralization | KG + DL |
| 13 | non-renal secondary hyperparathyroidism | KG + DL |
| 14 | bone remodeling disease | KG + DL |
| 15 | hyperparathyroidism, transient neonatal | KG + DL |
| 16 | hypocalcemic rickets | KG + DL |
| 17 | Worth syndrome | KG + DL |
| 18 | pregnancy associated osteoporosis | KG + DL |
| 19 | biotin metabolic disease | KG + DL |
| 20 | bone resorption disease | KG + DL |
| 21 | autosomal dominant neovascular inflammatory vitreoretinopathy | KG + DL |
| 22 | succinyl-CoA:3-ketoacid CoA transferase deficiency | KG + DL |
| 23 | hyperostosis | KG + DL |
| 24 | hereditary hypophosphatemic rickets with hypercalciuria | KG + DL |
| 25 | Donnai-Barrow syndrome | KG + DL |
| 26 | osteosclerosis | KG + DL |
| 27 | iron deficiency anemia | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.